Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials

“…Similarly, the discovery that some individuals who recovered from COVID‐19 had antibodies to interferon 62 raised the concern that some recipients may be worsened by CCP administration. Although recent studies have provided evidence that CCP with such antibodies was not harmful, 63 our results provide additional reassurance this regard. Finally, there was concern that CCP administration would blunt the immune response to SARS‐CoV‐2 but recent studies of participants in the C3PO trial showed no evidence that adaptive immune responses were affected 64 …”

Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma

“…Scott et al suggested that spike-protein proteolytic antibodies in CCP contribute to SARS-CoV-2 neutralization [18]. Cognasse et al also demonstrated that CCP exhibited moderately increased inflammatory markers on endothelial cells, neutralizing auto-Abs to type I IFNs compared to the control plasma with no discernible differences in ex vivo bioactivity [3]. CCP therapy with robust Fc-effector antiviral functions can serve as secondary defense when neutralization is compromised [19].…”

“…SARS-CoV-2 infection with respiratory presentation cannot be excluded after performing nasopharyngeal SARS-CoV-2 real-time reverse transcription-polymerase chain reaction (RT-PCR) [2]. Treatments for prolonged coronavirus disease 2019 (COVID-19) are rarely described and there are a lack of recommendations [3][4][5].…”

Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?

“…With only one inconclusive trial [13] , nobody really knows whether anti-SARS-CoV-2 IgG purified from these plasmas would be more efficient in Covid-19, but there are some reasons to think so. First, plasma is more than the collection of antibodies and could comprise some deleterious factors [14] , [15] . As a matter of fact, plasma comprises protective as well as non-protective Abs, not only in terms of epitope recognition (neutralizing vs non-neutralizing) but also in terms of classes, which vary in their biological effects and eventually on the clearance of viruses.…”